PharmaShots Weekly Snapshot (Sept 14 -18, 2020)

1. AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC

Published: Sept 18, 2020 | Tags: AstraZeneca, Reports, Updated Results, Imfinzi, P-III, Studies, NSCLC, ES-SCLC

2. Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Published: Sept 18, 2020 | Tags: Roche, Actemra, EMPACTA study, COVID-19, Pneumonia, Ventilation, Biologic, COVID-19 associated pneumonia

3. AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

Published: Sept 18, 2020 | Tags: AstraZeneca, MSD, Report, Five Year, Data, Lynparza, P-III, SOLO-1, Study, 1L Maintenance Treatment, Patients, BRCA-Mutated, Ovarian Cancer

4. Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Published: Sept 18, 2020 | Tags: Roche, Launches, Elecsys Anti-SARS-CoV-2 S, Test, COVID-19, Antibodies

5. Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Published: Sept 17, 2020 | Tags: Eli Lilly, Collaborates, Amgen, Boost, Global Supply, COVID-19 Therapies

6. AstraZeneca Acquires Dogma Therapeutics Oral PCSK9 Inhibitor Program

Published: Sept 17, 2020 | Tags: AstraZeneca, Acquires, Dogma Therapeutics, Oral, PCSK9 Inhibitor Program

7. Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020

Published: Sept 17, 2020 | Tags: Roche, Present, Oncology Portfolio, ESMO, Virtual Congress 2020

8. Junshi and Wigen Collaborate to Develop and Commercialize Four Therapies Targeting Cancer Indications

Published: Sept 16, 2020 | Tags: Junshi, Wigen, Collaborate, Develop, Commercialize, Four Therapies, Targeting, Cancer Indications

9. Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients

Published: Sept 16, 2020 | Tags: Sorrento, Initiate, P-I, Study, STI-1499, COVID-19, Positive, Patients

10. Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Published: Sept 16, 2020| Tags: Samsung Bioepis, Present, P-III, Exploratory Analyses, Results, Aybintio, bevacizumab, biosimilar, ESMO 2020

11. Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

Published: Sept 17, 2020 | Tags: Novartis, Reports, Results, Dual regimen, P-III, COMBI-AD Study, Patients, Stage III Melanoma

12. Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU

Published: Sept 16, 2020 | Tags: Baxter, Signs, Exclusive, Distribution, Agreement, bioMérieux, Acute Kidney Injury, Diagnostic Test, US, EU

13. Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting

Published: Sept 16, 2020 | Tags: Eli Lilly Reports POC Data of LY-CoV555 in P-II BLAZE-1 Study for COVID-19 in Outpatient Setting

14. Roche's CINtec PLUS Cytology Test Receives the US FDA's Approval to Aid Clinicians in Preventing Cervical Cancer

Published: Sept 15, 2020 | Tags: Roche, CINtec PLUS Cytology Test, Receives, US, FDA, Approval, Aid, Clinicians, Preventing, Cervical Cancer

15. Takeda to Divest TachoSil to Corza Health for ~$416M

Published: Sept 16, 2020 | Tags: Takeda, Divest, TachoSil, Corza Health, ~$416M

16. Gilead's Magrolimab Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndrome

Published: Sept 15, 2020 | Tags: Gilead, Magrolimab, US FDA, Breakthrough Therapy Designation, Myelodysplastic Syndrome, 2020 European Hematology Society Congress

17. BMS Exercises its Option to Globally License Obsidian's CD40L Cell Therapy

Published: Sept 15, 2020 | Tags: BMS, Exercises, Option, Globally, License, Obsidian, CD40L Cell Therapy

18. Merck's Brenzys (biosimilar, etanercept) Receives Health Canada Approval for Multiple Indications

Published: Sept 15, 2020 | Tags: Merck, Brenzys, biosimilar, etanercept, Receives, Health Canada, Approval, Multiple, Indications

19. Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Schizophrenia

Published: Sept 14, 2020 | Tags: Boehringer Ingelheim, BI 425809, Schizophrenia, ECNP Congress, Cognitive Impairment, CNS

20. The US FDA Rejects Mallinckrodt's Terlipressin Due to Doubts in its Risk-Benefit Profile

Published: Sept 14, 2020 | Tags: US, FDA, Rejects, Mallinckrodt, Terlipressin, Doubts, Risk-Benefit Profile

21. Novartis Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

Published: Sept 14, 2020 | Tags: Novartis, Beovu, brolucizumab, EMA Approval, Label Update, Safety Label, Wet AMD, Retinal Vasculitis, Retinal Vascular Occlusion, Intraocular Inflammation

22. Janssen Collaborates with SpringWorks Therapeutics to Evaluate Nirogacestat + Teclistamab for Relapsed or Refractory Multiple Myeloma

Published: Sept 14, 2020 | Tags: Janssen, Collaborates, SpringWorks Therapeutics, Evaluate, Nirogacestat, Teclistamab, Relapsed, Refractory, Multiple Myeloma

23. Eli Lilly and Incyte's Olumiant + Gilead's Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19

Published: Sept 14, 2020 | Tags: Eli Lilly, Incyte, Olumiant, Gilead, Veklury, Reduce Time, Recovery, Hospitalized Patients, COVID-19

24. Fitbit to Launch ECG App in the US and EU in October 2020

Published: Sept 14, 2020 | Tags: Fitbit, Launch, ECG App, US, EU, October, 2020, Fitbit Sense, AFib, ECG,

25. Merck Signs Up to $4.5B Oncology Deal with Seattle Genetics

Published: Sept 14, 2020 | Tags: Merck, Signs, Up to, $4.5B, Oncology Deal, Seattle Genetics

26. Boehringer Ingelheim and Click Collaborate on Digital Therapies for Behavior Modification in Schizophrenia

Published: Sept 13, 2020 | Tags: Boehringer Ingelheim, Click Therapeutics, Collaborate, Digital Therapeutic, Behavior Modification, Schizophrenia

27. Novartis Reports Results of Beovu (brolucizumab) in P-III KITE Study for Diabetic Macular Edema

Published: Sept 13, 2020 | Tags: Novartis, Reports, Results, Beovu, (brolucizumab), P-III, KITE Study, Diabetic Macular Edema

28. Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis

Published: Sept 13, 2020 | Tags: Sanofi, Dupixent, Receives, US, FDA, Breakthrough Therapy Designation, Eosinophilic Esophagitis